August 2026 Research Update

Across these papers, a consistent message was that Fabry disease is often considered during work-ups for thickened heart muscle or certain kidney imaging findings, but it can be confused with other causes. The research emphasized pattern recognition on heart imaging and careful selection of confirmatory testing, especially genetic testing, rather than relying on wall thickness alone. Evidence ranged from a large retrospective imaging analysis and cohort or registry data to smaller case-based reports and expert proposals. [1] [2] [3] [4] [5]

A large heart magnetic resonance imaging study found that a clearly uneven pattern where the wall between the ventricles is much thicker than the side wall was meaningfully more characteristic of hypertrophic cardiomyopathy than of other thick-heart conditions. This matters because asymmetric thickening was also seen in other causes of thickened heart muscle, including amyloidosis, so wall shape alone may not reliably separate these conditions without additional testing. [1]

An expert proposal focused on left ventricular hypertrophy suggested a two-step, phenotype-guided approach that combines medical history, electrocardiogram changes, and multiple heart imaging features, and then uses targeted blood and genetic tests to narrow the cause. It described how certain heart scan patterns can point toward Fabry (for example, low values on a particular MRI tissue measurement) while other patterns may suggest amyloidosis or hypertrophic cardiomyopathy. [2]

In a multicenter kidney cohort of 306 people with parapelvic cysts, 8 had a GLA gene variant (2.6%), including a smaller number with variants described as disease-causing. The authors interpreted this as a higher-than-expected rate compared with some other screened groups, raising parapelvic cysts as a potential clue that may sometimes prompt genetic evaluation for Fabry-related variants. [3]

A three-person case series showed that Fabry can present with a heart outflow obstruction and be mistaken for obstructive hypertrophic cardiomyopathy until genetic testing is done. In these individual cases, earlier treatments aimed at obstructive hypertrophic cardiomyopathy did not clearly address the underlying cause, while confirming a GLA mutation changed how the diagnosis was understood. [5]

A regional Italian registry describing a structured care pathway for people with a hypertrophic heart phenotype reported that Anderson-Fabry disease accounted for 4% of cases in that network. The report also noted that the number of patients followed at peripheral centers roughly doubled since 2021, and that about half of the centers had dedicated clinics, most with cardiologists experienced in these conditions, reflecting how organized pathways may help sort out different causes of thickened heart muscle, including Fabry. [4]

For patients and caregivers, this set of papers mainly provides background on why Fabry testing is often considered during evaluations for thickened heart muscle or certain kidney imaging findings, and why results can depend on using more than one clue. What is still uncertain is which specific patterns or patient groups should always trigger testing, because some evidence here comes from expert proposals and small case reports rather than studies designed to measure missed diagnoses.

These studies all focused on ways to track heart involvement in Fabry disease over time, using different scan-based measurements. Overall, they suggest that the pace of heart remodeling (how quickly structure changes) and specific measures of heart muscle function or inflammation may add useful information beyond a single snapshot. However, the evidence is mostly observational, and it is still uncertain which measures will best predict symptoms or outcomes across different Fabry populations. [6] [7] [8]

In a cohort of 105 East Asian patients, a higher starting level of structural heart involvement and a faster worsening trajectory (a steeper anatomical cardiac raw score slope) each independently linked to a higher chance of heart failure hospitalization or cardiovascular death over follow-up. The same study also reported that enzyme replacement therapy exposure was linked to a lower risk of this combined outcome, and that reduced kidney function changed the structural threshold tied to events. [6]

In 100 genetically confirmed patients, an automated ultrasound approach separated two right-heart strain measures that appeared to reflect different parts of heart involvement. Right-ventricle global strain related more to left-heart remodeling and a thicker wall between the ventricles, while right-ventricle free-wall strain related more to how the right atrium filled and emptied. Over time, among the 33 of 69 patients with repeat scans who had usable paired right-heart strain measurements, right-ventricle global strain changed differently in untreated versus enzyme replacement therapy treated patients, while free-wall strain did not show a similar pattern. [7]

In a small single-center study of 41 patients with repeat cardiac MRI, higher T2 mapping values (a scan measure often interpreted as inflammation-related) were seen in scarred heart regions on scans where the scar had newly appeared or grown since the previous scan, compared with scans where it was stable; because both were seen on the same scan, this does not yet show which comes first. In one part of the heart wall (the lower side wall near the base), T2 mapping was also higher on scans where scar had grown than on scans with no scar at all; the authors suggest this measure may help mark active disease, but only two of the comparisons reached statistical significance. [8]

For patients and caregivers, this body of research mainly supports the idea that repeated heart imaging can provide added context: not only how much the heart is affected now, but also whether it is changing quickly, and whether certain scan signals might come before scarring expands. Right now, these measures are better viewed as monitoring tools under study rather than definitive predictors for any one person, because the studies were not randomized and were limited to specific centers and populations. What remains uncertain is how well these scan-based measurements predict day-to-day symptoms and long-term outcomes across different Fabry gene variants and treatment histories. [6] [7] [8]

These papers point to a practical theme: Fabry treatment is sometimes adjusted over time, either by switching between enzyme infusions or using an oral option for certain gene variants, and the main outcomes tracked include symptoms, heart structure, blood markers, and infusion reactions. Evidence here ranges from single-patient case reports to one moderate-strength observational study, so results may not apply to everyone. Antidrug antibodies came up as an important factor for people receiving enzyme replacement therapy, especially in relation to infusion-associated reactions. [9] [10] [11]

In one pediatric case, a 12-year-old boy with classic Fabry disease switched from agalsidase alfa to agalsidase beta after an insufficient clinical and blood-marker response, and his episodic hand and foot pain improved while his plasma lyso-Gb3 level fell further after the switch. Anti-drug antibodies were detected both before and after the switch, and at his latest visit his heart ultrasound and kidney function tests were normal. Because this describes one child, it cannot show how often switching helps or which patients benefit most. [9]

In a separate 9-year case report of a 71-year-old woman with an amenable Fabry gene variant (N224S), long-term migalastat treatment was accompanied by a sustained downward trend in left ventricular mass index on echocardiography, with preserved pumping function and gradual improvement in measures related to heart relaxation. The report did not attribute adverse events to migalastat, but it also cannot prove cause and effect because it follows only one person. The main takeaway from this case is that long-term heart measurements can be tracked over many years during oral therapy when the gene variant is compatible. [10]

In a single-center observational study of classical males on enzyme replacement therapy, infusion-associated reactions were much more common among patients who had antidrug antibodies in a retrospective analysis. In a small prospective comparison, a stepwise dose-escalation start to agalsidase beta resulted in no infusion-associated reactions in 8 patients compared with reactions in 5 of 9 patients who started with the standard approach, but the stepwise start did not clearly reduce how often antibodies developed. This suggests infusion-start procedures may influence reaction risk even if antibody formation still occurs. [11]

For patients and caregivers, these reports mainly add background on what clinicians may monitor and why, rather than giving definitive answers about which treatment is best. The case reports show how individual goals can differ (pain control and blood markers in a child; long-term heart structure in an older adult on an oral option), while the observational study highlights that antibody testing and infusion reaction history can matter during enzyme infusions, and that changing how treatment is started may reduce infusion reactions in some settings. Important uncertainties remain, including how generalizable these single-center and single-patient results are and whether the same patterns hold over longer follow-up in broader groups.

Across these papers, Fabry disease was described as affecting more than just the heart, with signals involving blood vessels and the immune system. Two small observational studies reported measurable differences in blood vessel health tests and in circulating immune or inflammation-related blood markers compared with matched healthy controls, but they did not prove cause-and-effect or predict outcomes.

In a single-center study of 31 people with Fabry disease and 31 matched controls, blood vessel function was lower and carotid artery wall thickness was higher in Fabry disease. The same group also saw subtle differences on ultrasound heart scans, and the blood vessel measures tracked with the heart scan measurements; there were no differences between men and women in these vessel tests. [12]

In an exploratory cross-sectional study of 15 people with Fabry disease and 15 matched controls, several blood markers were higher in Fabry disease, including fibrinogen, a tumor necrosis factor pathway marker (sTNFR2), complement C4, and lymphocyte counts. When the researchers used pattern-finding methods, most Fabry patients grouped into a high-biomarker cluster, supporting a low-grade inflammation and complement activation profile in this sample. [13]

For patients and caregivers, these results mainly add background about whole-body effects of Fabry disease, especially how blood vessels and immune pathways may be involved even when symptoms are not obvious. Because the studies were small and mostly one-time measurements, it is still uncertain how well these tests predict future health changes or day-to-day symptoms.

This month included one report suggesting that, in rare situations, Fabry disease could show up in the lungs in an unusual way. Because the evidence comes from one person, it cannot show how common this is or whether it happens in other Fabry disease patients.

One 31-year-old woman with a family history of Fabry disease was found to have a single lung nodule that was removed and examined. Genetic testing identified a likely disease-causing GLA gene change (c.988C>G, p.Q330E), and the nodule tissue showed lipid-laden cells consistent with Fabry-type storage, while she had no other clear Fabry disease signs reported. [14]

The authors noted important uncertainties, including that some Fabry-specific tissue stains and electron microscopy were not done and certain blood markers were not measured. They discussed possible explanations such as tissue-specific buildup of storage material and differences in X-chromosome inactivation in women. [14]

This report matters most as a reminder that Fabry disease can have uncommon presentations outside the heart, including possible lung findings, but it is not enough to estimate risk for most patients. The key uncertainty is how often Fabry disease contributes to lung nodules and how confidently it can be confirmed without Fabry-specific tissue testing in larger studies.

Across these papers, the overall direction was toward mapping why Fabry disease affects organs differently and building lab models that let researchers test new therapy ideas in human cells. The strongest human data here were exploratory and focused on heart thickening in a specific genetic subgroup, while the rest were preclinical resources and lab experiments that cannot yet tell how a treatment would work in people. [15] [16] [17] [18] [19] [20]

In a genetic analysis of 81 men aged 50 or older with the IVS4+919G>A founder variant, one DNA region near EGLN1/SPRTN was linked to lower left-ventricular mass, meaning less heart thickening in the group studied. The same study did not find a clear, genome-wide genetic signal tied to a single blood measurement of lyso-Gb3, and the authors noted that independent replication is needed. [15]

Several teams created induced pluripotent stem cell (iPSC) lines from Fabry patients, which are patient-derived cells that can be grown and then turned into different cell types for research. These included a urine-derived iPSC line from a man with a kidney-dominant phenotype due to the p.Gly361del change in GLA, plus multiple iPSC lines from women with heterozygous GLA variants, including one set with an isogenic control line (a closely matched comparison line). These resources mainly add tools for studying Fabry kidney and other organ biology and for screening potential drugs in the lab. [16] [17] [18]

In lab-grown heart muscle cells made from iPSCs, a nucleoside-modified mRNA that encodes alpha-galactosidase A (modGLA) increased enzyme activity and reduced the stored fat Gb3 inside cells, and it also improved certain cell readouts linked to abnormal calcium handling. The study reported these effects in both gene-knockout and patient-derived cell models and also showed that lipid nanoparticle delivery increased enzyme activity in additional lab tissues, but it did not test clinical outcomes in patients. [19]

Another preclinical study used computer simulations to describe how the human enzyme A4GALT carries out a key chemical step that produces Gb3, then designed a Gb3-related molecule (AdaGalCer) based on that mechanism. In fibroblast cells, AdaGalCer reduced Gb3 production while being converted to a related product (AdaGb2), showing a possible route to lowering Gb3 by targeting its production pathway in cells. [20]

For patients and caregivers, this set of studies mainly matters as background research that can shape future therapy development and explain why organ involvement (especially in the heart) may vary between people. The genetic result applies only to men with one specific founder variant and needs confirmation before it can be considered reliable for broader use. The iPSC lines and lab experiments help researchers test ideas (like mRNA delivery of alpha-galactosidase A or reducing Gb3 production) in human cells, but they do not show whether these approaches are safe or effective in people yet, or which symptoms or organ outcomes they would change.